ArticleArthritis research & therapy2025
M-CSF, inducing CD163 macrophages, is associated with severity and prognosis of glomerulonephritis in microscopic polyangiitis.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRapid progressive glomerulonephritis (RPGN) is a severe complication of microscopic polyangiitis (MPA), leading to end-stage renal disease (ESRD). However, biomarkers for assessing the disease severity have not been elucidated in MPA-RPGN. The aim in this exploratory hypothesis-generating study was to identify serum biomarkers associated with renal disease severity and prognosis in patients with MPA.
methodsThis study enrolled 73 patients with MPA. We measured 16 serum biomarker profiles, and compared them between patients with MPA with RPGN and those without RPGN. We identified biomarkers with higher levels in MPA with RPGN and evaluated their associations with progression to ESRD. Five kidney biopsy specimens were examined by haematoxylin and eosin staining and immunostaining to evaluate the biomarker expressions.
resultsOf the 73 patients, 30 patients (41.1%) had RPGN on admission. Initial serum M-CSF levels and TNF-a levels were significantly higher in patients with MPA with RPGN than those without RPGN. Among them, serum M-CSF levels significantly correlated with glomerular and renal tubular damage markers. The 5-year ESRD-progression rate was significantly higher in patients with initial serum M-CSF ≥ 416.95 pg/ml than in patients with serum M-CSF < 416.95 pg/ml (P = 0.0002). Immunohistochemical staining showed enhanced M-CSF expression in glomerular capillary endothelial cells and tubular epithelial cells in cases with severe glomerular and tubular damage. CD163-positive macrophages showed high infiltration into the periglomerular and peritubular areas in the sclerotic group.
conclusionsThe serum M-CSF level may serve as a biomarker that reflects RPGN severity and predicts progression to ESRD in patients with MPA. M-CSF-inducing CD163 + macrophages might contribute to the pathogenesis of RPGN in MPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.